On February 15, 2024, Freenome, a biotechnology company developing blood tests for early cancer detection, announced it has raised $254 million in new funding from new and existing investors. Proceeds from the financing will help advance Freenome’s pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform. Wilson Sonsini Goodrich & Rosati advised Freenome on IP matters related to the transaction.

The latest funding round was led by Roche, joined by a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital Life Sciences, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, with funds and accounts advised by T. Rowe Price Associates, Inc., and others.

The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, and Carmen Chow.

For more information, please see Freenome's news release. Additional coverage can be found on Reuters, BioSpace, and Fierce Biotech.